AlloVir Stock

allovir.comHealthcareFunding to Date: $154.35MM

AlloVir is a biotechnology specializing in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Register for Details

For more details on financing and valuation for AlloVir, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for AlloVir.

Register Today

Team

Management Team

Ann Leen Ph.D
Chief Scientific Officer & Co-Founder
Juan Vera MD
Co-Founder, Chief Product Development Officer & Board Member
Cliona Rooney Ph.D
Advisor
David Hallal
Chief Executive Officer & Chairman
Helen Heslop MD
Co-Founder & Advisor
Elizabeth Stoner MD
Senior Clinical Advisor
Vikas Sinha
President, Chief Financial Officer & Board Member
Mitchell Finer Ph.D
Advisor

Board Members

John Wilson
Morana Jovan-Embiricos
David Hallal
Malcolm Brenner MD
Ansbert Gadicke
Juan Vera MD
Vikas Sinha

Other companies like AlloVir in the Healthcare sector

Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$4.8B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM